

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form NT 10-K

ELITE PHARMACEUTICALS INC /DE/  
Form NT 10-K  
June 30, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 12b-25

Notification of Late Filing

SEC File Number 333-45241  
CUSIP Number 28659T200

(Check One):

Form 10-K and Form 20-F  Form 11-K  Form 10-Q and  
 Form N-SAR

For Period Ended: March 31, 2003

Transition Report on Form 10-K  
 Transition Report on Form 20-F  
 Transition Report on Form 11-K  
 Transition Report on Form 10-Q  
 Transition Report on Form N-SAR

For the Transition Period Ended: \_\_\_\_\_

READ INSTRUCTION (ON BACK PAGE) BEFORE PREPARING FORM. PLEASE PRINT OR TYPE.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

-----  
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

N/A

-----  
PART I - REGISTRANT INFORMATION

Full Name of Registrant	ELITE PHARMACEUTICALS, INC.
Former Name if Applicable	N/A
Address of Principal Executive Office (STREET AND NUMBER)	165 LUDLOW AVENUE NORTHVALE, NEW JERSEY 06830

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate).

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form NT 10-K

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report, or portion thereof, could not be filed within the prescribed time period.

(Attach extra sheets if needed).

Elite Pharmaceuticals, Inc. (the "Company") is not able to file its Annual Report on Form 10-K for the year ended March 31, 2003 (the Form 10-K) within the time period prescribed for such report without unreasonable effort or expense.

As previously reported, the Company's chief executive officer, Atul M. Mehta, terminated his employment with the Company on June 3, 2003. The termination by Dr. Mehta of his employment, and the change in chief executive officer as a result, has caused unavoidable delay in the completion of the Company's Annual Report on Form 10-K for the year ended March 31, 2003.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification.

Mark I. Gittelman, Chief Financial Officer	(201)	750-2646
-----		
(Name and Title)	(Area Code)	(Telephone Number)

(2) Have all other periodic reports required under Sections 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes                       No

-2-

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes                       No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form NT 10-K

estimate of the results cannot be made.

Elite Pharmaceuticals, Inc.

-----  
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

ELITE PHARMACEUTICALS, INC.

Date: June 30, 2003

By: /s / Mark I. Gittelman

-----  
Name: Mark I. Gittelman  
Title: Chief Financial Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

-----ATTENTION-----

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)

-----  
GENERAL INSTRUCTIONS

1. This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934.
2. One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act. The

-3-

information contained in or filed with the form will be made a matter of public record in the Commission files.

3. A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class of securities of the registrant is registered.
4. Amendments to the notifications must also be filed on Form 12b-25 but need not restate information that has been correctly furnished. The form shall be clearly identified as an amended notification.
5. Electronic Filers. This form shall not be used by electronic filers unable to timely file a report solely due to electronic difficulties. Filers unable to submit a report within the time period prescribed due to difficulties in electronic filing should comply with either Rule 201 or

**Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form NT 10-K**

Rule 202 of Regulation S-T (ss.232.201 or ss.232.202) of this chapter or apply for an adjustment in filing date pursuant to Rule 13(b) of Regulation S-T (ss.232.13(b) of this chapter).